Peptide therapy has taken the wellness and biohacking worlds by storm. Among the most talked-about options is , a synthetic growth hormone-releasing hormone (GHRH) analogue.
Tesamorelin was originally FDA-approved in 2010 (under the brand name Egrifta ) to treat visceral fat accumulation (lipodystrophy) in patients living with HIV. tesamorelin buy
Clinical studies show that fat loss from tesamorelin is highly dependent on continued use; the visceral fat typically returns once the protocol stops. 🛑 The Dangers of Buying Tesamorelin Online Peptide therapy has taken the wellness and biohacking